MichaelRTranfagliaMD

Psychiatry • Newburyport, MA

Neuropsychiatry, Psychopharmacology

Medical Director Chief Scientific Officer FRAXA Research Foundation

Join to view full profile

Dr. Tranfaglia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tranfaglia's full profile

Already have an account?

Office
10 Prince Place
suite 203
Newburyport, MA 01950
Phone+1 978-462-1866
Is this information wrong?

Education & Training

University of North Carolina HospitalsResidency, Psychiatry, 1987 - 1991
University of North Carolina at Chapel Hill School of MedicineClass of 1987

Certifications & Licensure

MA State Medical License 1991 - 2025

Publications & Presentations

PubMed

1 citations
A novel combination treatment for fragile X syndrome predicted using computational methods.
Chadwick, W., Angulo-Herrera, I., Cogram, P., Deacon, R., Mason, D., Brown, D., Roberts, I., O'Donovan, D., Guilliams, T., Thompson, N., Tranfaglia, M.> ;Brain Communications. 2024 Jan 1
24 citations
Repurposing available drugs for neurodevelopmental disorders: The fragile X experience.
Michael Tranfaglia, Clare Thibodeaux, Daniel J. Mason, David R. Brown, Ian Roberts, Richard Smith, Tim Guilliams, Patricia Cogram> ;Neuropharmacology. 2019 Mar 15
43 citations
PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.
Catherine H. Choi, Brian P. Schoenfeld, Eliana D. Weisz, Aaron J. Bell, Daniel B. Chambers, Joseph Hinchey, Richard J. Choi, Paul Hinchey, Maria Kollaros, Michael Gert...> ;The Journal of Neuroscience. 2015 Jan 7
88 citations
Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Cara J. Westmark, Pamela R. Westmark, Kenneth J. O’Riordan, Brian C. Ray, Crystal Hervey, M. Shahriar Salamat, Sara Abozeid, Kelsey M. Stein, Levi A. Stodola, Michael ...> ;Plos One. 2011 Oct 26
13 citations
Fragile X syndrome: a psychiatric perspective.
Michael R. Tranfaglia> ;Results and Problems in Cell Differentiation. 2012 Jan 1
57 citations
The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.
Michael Tranfaglia> ;Developmental Neuroscience. 2011 Jan 1
83 citations
Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment
Catherine H. Choi, Brian P. Schoenfeld, Aaron J. Bell, Paul Hinchey, Maria Kollaros, Michael Gertner, Newton H. Woo, Michael R. Tranfaglia, Mark F. Bear, R. Suzanne Zu...> ;Brain Research. 2011 Mar 22
159 citations
Open-label add-on treatment trial of minocycline in fragile X syndrome
Carlo Paribello, Leeping Tao, Anthony Folino, Elizabeth Berry-Kravis, Michael Tranfaglia, Iryna M. Ethell, Douglas W. Ethell> ;BMC Neurology. 2010 Oct 11
269 citations
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Elizabeth Berry-Kravis, David R Hessl, Sarah M. Coffey, Crystal Hervey, Andrea Schneider, Jennifer Yuhas, Julie A Hutchison, Michael Snape, Michael Tranfaglia, Danh V....> ;Journal of Medical Genetics. 2009 Jan 6
387 citations
Advances in the treatment of fragile x Syndrome
Randi J Hagerman, Elizabeth Berry-Kravis, Michele Y. Ono, Nicole Tartaglia, Ave M. Lachiewicz, Rebecca Kronk, Carol Delahunty, David R Hessl, Jeannie Visootsak, Jonath...> ;Pediatrics. 2009 Jan 1
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Yan, Q. J., Rammal, M., Tranfaglia, M., Bauchwitz, R. P.> ;Neuropharmacology. 2005 Dec
Join now to see all

Press Mentions

UK Startup Healx to Begin Clinical Trial on Repositioned Drug for Fragile X SyndromeOctober 20th, 2021
Study Shows Fragile X Treatment Can Incur Resistance, Suggests Ways Around ItSeptember 29th, 2021
Synaptogenix Signs Memorandum of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X SyndromeAugust 5th, 2021
Join now to see all